The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
#EULAR2024: Interleukin inhibitors
To update you on the exciting content presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, we have collated our social media coverage. Catch up with our live social media relating to interleukin (IL) inhibitors, here.
CONGRESS #EULAR2024 | POSTER: Dr. Saakshi Khattri presented a poster on Week 16 results of the VISIBLE trial in skin of color patients. Compared to placebo, after 3 doses of guselkumab a significantly increased proportion of patients achieved IGA 0/1 and PASI 90. There were no… pic.twitter.com/Em5V1EQnGe
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024
CONGRESS #EULAR2024 | POSTER: Dr. Philip J. Mease presented a poster on real-world data comparing treatment persistance of guselkumab vs IL-17 inhibitors for PsA. Patients receiving guselkumab were 2x more likely to remain on treatment to 12 months vs IL-17i. #psoriaticarthritis pic.twitter.com/EAWKGRylmp
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024
CONGRESS #EULAR2024 | POSTER: @DrLauraCoates presented a poster on the phase III BE OPTIMAL and BE COMPLETE trials. Regardless of prior bDMARD treatment, patients treated with bimekizumab showed sustained response in MDA and DAPSA over 2 years. There were no new safety signals.… pic.twitter.com/zTdxnGDCvb
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024
CONGRESS #EULAR2024 | POSTER: @DrLauraCoates presented a poster with data from the phase IIIb COSMOS trial. Patienst treated with guselkumab were significantly more likely ro achieve improved pain VAS outcomes compared to placebo at Week 8, and response rates increased through… pic.twitter.com/bjN12iRVNA
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 13, 2024
CONGRESS #EULAR2024 | @IainBMcInnes1 presented 12 week data on sonelokimab from the phase II ARGO trial. Endpoints of ACR20, ACR50, and PASI 90 were all met at Week 12. There were no unexpected safety findings. #psoriasis #psoriaticarthritis pic.twitter.com/X0x6GvuQxX
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 13, 2024
CONGRESS #EULAR2024 | Irakli Tskhakaia discussed an analysis of cardiovascular outcomes after TNFa and IL-17 inhibtors treatment in PsA. Retrospective analysis showed almost double the risk of cardiovascular disease with use of TNF-a inhibitor vs IL-17 inhibitor.… pic.twitter.com/vzoshqEank
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 12, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content